Often, more money is collected from patients on medicines, which makes them face difficulties. With the aim of preventing this exploitation, the National Pharmaceutical Pricing Authority (NPPA) has set the maximum price threshold for nine drug formulations. So that, affordable medicines can be available to patients for select treatments.
Among the drugs whose maximum price limit is imposed by the NPPA is Tacrolimus. This is an immunosuppressive drug used to reduce risks after transplantation. Additionally, the price of Co-trimoxazole has also been fixed. It is used for the treatment of bacterial infections causing pneumonia and also in urinary tract infections.
The NPPA has determined the ceiling price of Tacrolimus (0.5 milligrams) at ₹20.97. The prices for Tacrolimus 1 milligram and 2 milligrams are set at ₹39.98 and ₹77.69, respectively. According to the notification issued by the department, if the maximum retail price of any formulation is not immediately complied with, the relevant manufacturer or marketing company will face action. In accordance with the provisions of DPCO 2013, these companies will also have to deposit an additional amount with interest.
According to the latest order from the NPPA, the maximum price of Co-trimoxazole is set at ₹2.30, and the price of Zinc Sulfate tablet (20 milligrams) is set at ₹3.41. Additionally, the NPPA has revised the maximum price of the pain reliever Tramadol (50 milligrams) to ₹9.70. The price of the cancer treatment drug Temozolomide (20 milligrams) has been fixed at ₹336.63. The NPPA order states that, in accordance with the Drug Price Control Order, 2013, the authority has extended the maximum price limit on orthopedic knee implants for another year until September 15, 2024.
Download Money9 App for the latest updates on Personal Finance.